We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600549:SSEXiamen Tungsten Co. Ltd. Class A Analysis

Data as of 2026-07-10 - not real-time

CN¥64.67

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Xiamen Tungsten is trading at CNY 64.67, well above its DCF‑derived fair value of roughly CNY 6.9, indicating significant overvaluation. The stock sits below its 20‑day SMA (CNY 77.79) and just under the 50‑day SMA (CNY 65.23), while remaining above the 200‑day SMA (CNY 51.18), suggesting mixed medium‑term momentum. Technical momentum is further dampened by a bearish MACD signal and a negative histogram, while the RSI at 40.8 points to a lack of buying pressure. Volatility is exceptionally high at 88% over the past 30 days, yet the beta is low (≈0.28), implying that price swings are largely company‑specific rather than market‑driven. Fundamental metrics reinforce the valuation concern: a trailing PE of 33.9 and a price‑to‑book of 5.6 are well above industry norms, and free cash flow is negative despite positive operating cash flow. The company delivers strong top‑line growth (87% revenue increase) and a modest dividend yield of 1.55% with a payout ratio of 31.6%, but the high debt‑to‑equity ratio (54%) and negative free cash flow raise questions about dividend sustainability.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish MACD and price below short‑term SMAs
  • Extreme overvaluation relative to DCF fair value
  • High 30‑day volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and market position in tungsten and related metals
  • Continued dividend payout despite cash flow constraints
  • Persistent valuation gap limiting upside

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Long‑term demand for tungsten, molybdenum and battery materials
  • Potential for balance‑sheet improvement and cash‑flow generation
  • Valuation compression risk if market re‑prices fundamentals

Key Metrics & Analysis

Financial Health

Revenue Growth87.00%
Profit Margin5.66%
P/E Ratio33.9
ROE16.85%
ROA6.51%
Debt/Equity54.07
P/B Ratio5.6
Op. Cash FlowCN¥795.1M
Free Cash FlowCN¥-2288632064

Technical Analysis

TrendBullish
RSI40.8
SupportCN¥60.45
ResistanceCN¥96.85
MA 20CN¥77.79
MA 50CN¥65.23
MA 200CN¥51.18
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14

Valuation

Fair ValueCN¥6.87
GradeOvervalued
TypeGrowth
Dividend Yield1.55%

Risk Assessment

Beta0.29
Volatility87.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.